evaluation of topical niosomal zinc sulphate in leishmaniasis
Phase 2
Recruiting
- Conditions
- Acute cutaneous leishmaniaisis.Cutaneous leishmaniasis
- Registration Number
- IRCT20170806035524N4
- Lead Sponsor
- Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
acute cutaneous leishmaniasis(urban type)
duration less than 6 months
wash out period of 1 month
Exclusion Criteria
pregnancy
nursing
age less than 2 years old
number of lesions more than 5
sensitization to zinc sulphate or glucantime
lesions on face or joint
lesions larger than 5 centimeter
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in induration of the lesion. Timepoint: at BASE -LINE AND IN 2,4,6,8,10,12 WEEKS and 3 months after end of the treatment. Method of measurement: by measuring induration of the lesions (largest diameter) by transparent paper.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie niosomal zinc sulfate's efficacy in cutaneous leishmaniasis?
How does topical niosomal zinc sulfate compare to cryotherapy in treating acute cutaneous leishmaniasis?
Are there specific biomarkers that predict response to niosomal zinc sulfate in leishmaniasis patients?
What are the potential adverse events associated with niosomal zinc sulfate and intralesional glucantime combination therapy?
What is the therapeutic potential of niosomal formulations in leishmaniasis compared to traditional drug delivery methods?